Background Seizures and their consequences contribute to the burden of epilepsy because they can cause health loss (premature mortality and residual disability). Data on the burden of epilepsy are needed for health-care planning and resource allocation. The aim of this study was to quantify health loss due to epilepsy by age, sex, year, and location using data from the Global Burden of Diseases, Injuries, and Risk Factors Study.
Introduction
Epilepsy is a chronic disease of the CNS that affects individuals of all ages and has a worldwide distribution. 1 The cardinal manifestations of epilepsy are epileptic seizures: that is, recurrent paroxysmal events character ised by stereotyped behavioural alter ations reflecting the neural mechanisms involved in the epileptic process. 2 Several diseases and injuries are implicated in the origin of epileptic seizures, with variable distribution in the world.
1 Although many underlying disease mechanisms can lead to epilepsy, the cause of the disease is still unknown in about 50% of global cases. 1 The diagnosis of epileptic seizures and epilepsy and ascertainment of the cause are difficult tasks, especially in lowincome countries where socio economic and cultural constraints are obstacles to the recognition and acceptance of the disease. 3 These limitations, along with the differing distribution of some environmental risk factors, are
Added value of this study
This systematic analysis for GBD 2016 is specifically aimed at informing epilepsy researchers and clinicians who might not have seen the general publications on this global public health resource. We present results on the burden of active idiopathic epilepsy (ie, epilepsy of genetic or unknown origin), exploring variation by age, sex, location, and year, as well as the association between epilepsy burden and development status of a country, as measured by the Socio-demographic Index (SDI), a compound measure of income per capita, education, and fertility. About the same number of people globally have idiopathic and secondary epilepsy. There is little variation by SDI in prevalence of idiopathic epilepsy, with rates in the five SDI quintiles of countries indistinguishable from the global age-standardised rate of 326·7 per 100 000 population (278·4-378·1) in 2016. Two-thirds of the gap in burden from idiopathic epilepsy between SDI quintiles is due to longer survival in people with epilepsy, and another third is from lesser severity of disease in high SDI quintile countries.
Implications of all the available evidence
From 1990 to 2016, significant changes in the burden of idiopathic epilepsy have been observed. These changes resulted from reduction in the case fatality rate and severity of disease rather than a change in prevalence. The low mortality rate in high SDI countries suggests that further gains can still be made in low and middle SDI countries because deaths from idiopathic epilepsy are largely avoidable with adequate management of the disease. Similarly, improved access to treatment can reduce burden by shifting people with epilepsy out of the state of recurrent seizures. The causes of secondary epilepsy are more amenable to prevention; although treatments can lead to the same successful control of seizures, they have less successful treatment overall because they do not address the often-severe comorbid disabilities from motor or intellectual impairments. In future GBDs, it would be advisable to explicitly aggregate all of the causes of secondary epilepsy that are currently estimated as sequelae (consequences) of underlying diseases and often in combined sequelae with motor, cognitive, or sensory impairments.
(including agespecific, sexspecific, timespecific, and geographical trends, and the sociodemographic context) was needed to make the information more accessible to researchers, clinicians, and planners of neurological services. We aimed to quantify health loss due to epilepsy by age, sex, year, and location using data from the GBD collaboration in 195 countries and territories from 1990 to 2016.
Methods Overview
Details of the general GBD methodology are reported in the appendix, including the guiding principles to assess health loss, the selection and assessment of the quality of the data sources, the input data and modelling strategies to assess epilepsy mortality and impairment, and a list of key articles used for reference.
Mortality
To assess premature mortality, we adhered to the underlying cause of death recorded in vital registration systems, as assigned by a physician on a death certificate. We made extensive corrections to cause of death data by redistributing deaths that were assigned to unspecified or intermediary causes on the basis of the International Classification of Diseases (ICD). The ICD9 code for epilepsy is 345 and the ICD10 codes for epilepsy are G40 and G41. Mortality from epilepsy was modelled with the Cause of Death Ensemble model, a tool devel oped for GBD cause of death analysis. The Cause of Death Ensemble model has the ability, through outof sample predictive validity testing, to determine which combination of covariates produces estimates that best cover the input data. This approach is different from analyses done to prove causality between a covariate or risk and an out come. The data inputs in the model included 16 533 siteyears of vital registration and 1093 siteyears of verbal autopsy data; a siteyear is a unique combination of location and calendar year. The model also included predictive covariates on pigs per capita and pig meat consumption as a proxy for neurocysticercosis infection, 10, 11 systolic blood pressure, cholesterol, 12 a measure of healthcare access and quality, 13 and a summary exposure measure of alcohol con sumption. 14 Additional details on calculations can be found in the GBD 2016 risk factor overview paper 15 and in the appendix.
Non-fatal disease modelling
The reference definition for epilepsy was based on the International League Against Epilepsy (ILAE) Guidelines for Epidemiologic Studies on Epilepsy, 16 which defined an epilepsy case as someone with an active, recurrent condition of epileptic seizures (two or more) unprovoked by an immediate cause and who has had at least one epileptic seizure in the past 5 years regardless of antiepileptic drug treatment.
Systematic review of the literature yielded 319 unique sources of data on prevalence covering 20 of the 21 world regions, 82 unique sources of data on incidence covering 15 of the 21 world regions, and three unique sources of data on remission covering three of the 21 world regions. We also added 3 years of medical claims data from the USA. These data were defined in ICD9 terms. The other sources of prevalence and incidence data were surveys stating case definitions independent of ICD codes.
Oceania was the only region for which no data were available. All data sources reported on all epilepsy (idiopathic and secondary combined). Where datapoints spanned an age group of more than 20 years, we split these data points into 5year age bands by applying the age pattern from the USA, for which we had the most detailed data by age.
We modelled overall epilepsy prevalence and incidence using DisModMR 2.1, the Bayesian metaregression tool developed for GBD. Study covariates were included to adjust US claims data to the reference epidemiological definition and to adjust studies with data on lifetime history of epilepsy to our active epilepsy definition. Additionally, we used a summary exposure measure of alcohol consumption and pig meat consumption per capita as predictive covariates on prevalence, as well as lagdistributed income as a predictive covariate on the excess mortality rate, or the excess rate of dying in cases of epilepsy in comparison with the general population.
Idiopathic and secondary epilepsy
The overall epilepsy prevalence derived from this model was split into idiopathic epilepsy (ie, epilepsy due to a genetic cause or when diagnostic assessment did not reveal a causative factor) and secondary epilepsy (ie, epi lepsy due to structural, metabolic, infective, or immune cause).
The term idiopathic is in accordance with the 1985 ILAE proposal for classification of epilepsies and epileptic syndromes. 17 Although this terminology has been questioned in the latest ILAE classification of the epilepsies, 18 we retained the old term because most of the epidemiological studies used as data sources adopted the old classification.
From a systematic review, we identified 89 unique sources of data reporting on the proportion of epilepsy that is due to genetic or unknown causes, covering 18 of the 21 world regions. We found, however, that not all the sources identified used advanced diagnostic methods (CT or MRI scans in addition to electroencephalograms) to diagnose secondary epilepsy, and that sources that did not use advanced diagnostic methods reported systematically lower proportions for secondary epilepsy. Therefore, we added a covariate to adjust the studies with less comprehensive diagnostic procedures to those that used all available methods to diagnose secondary epilepsy. We used these data in a linear mixedeffects model, with fixed effects on under5 mortality rate, logtransformed pig meat consumption, access to sanitation, and the study quality covariate, as well as random effects for super regions (ie, seven aggregates of 21 world regions defined in GBD). We obtained predictions for the proportion of idiopathic epilepsy from this model for every location and year, and applied them to the preva lence and incidence results of the DisModMR 2.1 model to calculate the prevalence and incidence of idiopathic epilepsy.
Secondary epilepsy was quantified as longterm con sequences of meningitis, tetanus, malaria, cysticercosis, cystic echinococcosis, preterm birth complications, neo natal encephalopathy, neonatal sepsis, and neonatal haemolytic disease. Secondary epilepsy from other causes, such as brain cancer, traumatic brain injury, congenital anomalies, or stroke, was not quantified explicitly but assumed to be subsumed in the severity distributions and corresponding disability weights for those conditions.
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Severity distributions and years lived with disability
Three health states were defined as sequelae of idiopathic epilepsy: severe epilepsy, defined as an average seizure frequency of more than or equal to once per month; less severe epilepsy with a seizure frequency of less than once a month, or no seizures in the past year while untreated but still fulfilling the criteria of active epilepsy; and seizurefree, treated epilepsy, defined as not having seizures in the past year while on treatment. All the data informing these splits were identified through systematic review. The data included 29 unique sources on the proportion of epilepsy that is severe, covering 12 of the 21 world regions; 68 unique sources on the proportion of epilepsy that is treated, covering 16 of the 21 world regions; and ten unique sources on the proportion of treated patients with epilepsy who do not have seizures, covering six of the 21 world regions. The distributions of cases across these three health states were quantified in three additional linear models. The first two splits, to derive the proportion of less severe epilepsy and then to calculate the proportion of less severe epilepsy that is treated, used linear models with a fixed effect on the index of healthcare access and quality and random effects on superregion. To determine the proportion of treated epilepsy where patients had not reported seizures in the previous year, we ran a linear regression with a fixed effect on the index of healthcare access and quality. We split out the prevalence and incidence for these categories by sequentially applying the proportions to the prevalence and incidence of idiopathic epilepsy. The final category of less severe epilepsy was calculated as the overall less severe epilepsy category, excluding treated epilepsy with out seizures. Each one of the three severity categories has a specific disability weight, and years lived with disability (YLDs) were calculated as prevalence multiplied by the categoryspecific disability weight. Further details on the methodology are provided in the appendix.
Socio-demographic Index
The frequency and severity of epilepsy were also assessed with reference to the Sociodemographic Index (SDI), a composite measure developed to provide a comparable metric of overall socioeconomic development in each country and represented by the gross domestic product per capita, the average years of education in the population older than 15 years of age, and the total fertility rate. 20 
Risk estimation
Alcohol use was the only risk of the 84 risks included in GBD 2016 for which there was deemed to be sufficient evidence for a causal relationship with idiopathic epilepsy as an outcome. Populationattributable fractions were estimated using data for exposure, relative risk, and a theoreticalminimum exposure level. Additional details on calculations can be found in the GBD 2016 risk factor overview paper. 15 
Compilation of results
Years of life lost (YLLs) were calculated by multiplying the number of deaths at each age group by the remaining life expectancy at that age, which was derived from the GBD standard life table. 21 DALYs were then calculated by summing YLLs and YLDs. We propagated uncertainty at each step of the analytical process by sampling 1000 draws at each computational step. Uncertainty intervals (UIs) were defined as the 25th and 975th values of the ordered draws. The term rate was used to indicate the number of cases per 100 000 population, in keeping with the other GBD reports. Differences in rates and counts between 1990 and 2016 are presented as significant if more than 950 of 1000 draws were all negative, or all positive. The study is compliant with the Guidelines for Accurate and Transparent Health Estimates Reporting (appendix).
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or the writing of the report. All authors had full access to the data in the study and had final responsibility for the decision to submit for publication.
Results
In 2016, there were 45·9 million (95% UI 39·9-54·6) individuals with active epilepsy of idiopathic or second ary nature globally. Of these individuals, 24·0 million (20·4-27·7) had active idiopathic epilepsy. There were 126 055 epilepsyrelated deaths (118 632-135 517) and 13·5 million DALYs (11·0-16·5; table 1), and there were 5·9 million (5·6-6·4) YLLs and 7·5 million (5·1-10·5) YLDs. Idiopathic epilepsy accounted for 0·23% (0·22-0·25) of deaths and 0·56% (0·48-0·66) of DALYs from all causes. Global agestandardised mortality rates of idiopathic epilepsy were 1·74 per 100 000 popu lation (1·64-1·87; 1·40 per 100 000 population [1·23-1·54] for women and 2·09 per 100 000 population [1·96-2·25] for men).
Globally, in 2016, there were 1·4 million (95% UI 1·2-1·6) idiopathic epilepsy cases in men and 1·3 million (1·1-1·6) cases in women, with agestandardised inci dence rates of 38·9 per 100 000 personyears (32·7-45·7) for men and 37·1 per 100 000 personyears (30·8-44·1) for women. Between 1990 and 2016, there were no signifi cant changes in both agestandardised incidence rates Prevalence per 100 000 population
In 2016, the global agestandardised prevalence of all active epilepsy (idiopathic and secondary) was 621·5 per 100 000 population (95% UI 540·1-737·0). It varied from a low of 311·0 per 100 000 pop ulation (253·4-370·5) in Japan to a high of 1287·7 per 100 000 population (754·4-1791·3) in Cape Verde. The prevalence of idiopathic epilepsy was 326·7 per 100 000 population (278·4-378·1). The prevalence was 329·3 per 100 000 population (280·3-381·2) in men and 318·9 per 100 000 population (271·1-369·4) in women. Highest prevalence was found in eastern, western, and For further details on prevalence, incidence, deaths, DALYs, YLLs, and YLDs for both sexes, all ages, countries, and territories, please refer to the GBD Results Tool.
Counts for prevalent cases, deaths, and DALYs, and the corresponding percentage change in agestandardised rates between 1990 and 2016 of idiopathic epilepsy, varied across countries (table 1) . There was a signifi cant differ ence in agestandardised prevalence of idio pathic epilepsy in 2016, ranging from 648·9 per 100 000 population (95% UI 222·8-1012·3) in Botswana to 139·7 per 100 000 population (20·1-366·9) in the Central African Republic. The wide UIs, in part, reflect the heterogeneity of data sources for the estimates of all epilepsy. However, the largest source of uncertainty comes from modelling the sparse data on the proportion of all epilepsy that is idiopathic or secondary to other causes. No region, or even country, had a significant change in agestandardised prevalence between 1990 and 2016. Agestandardised mortality rates of idiopathic epilepsy decreased significantly in 74 countries, mostly from western and central Europe, Australasia, high income North America, highincome Asia Pacific, Latin America, the Caribbean, and north Africa and the Middle East. By contrast, mortality rates increased in 22 countries, predominantly from western subSaharan Africa, and occasionally also from Europe (Belgium, Denmark, Germany, Iceland, and Poland) and southeast Asia (Thailand). As a consequence of changes in mortality rates and subsequently YLL rates of idiopathic epilepsy, agestandardised DALY rates decreased signifi cantly in central Latin America, east Asia, south Asia, (table 1) . However, in individual countries, a significant decrease was found only in the UK, Mexico, China, Bangladesh, and India. Because of the wide UIs around prevalence, no country experienced a significant change between 1990 and 2016 (table 1) . By contrast, the reduction of agestandardised deaths varied by SDI quintiles, with large reductions in the three middle SDI quintiles, but no significant change in the low and high SDI quintiles. Expected values of agestandardised DALY rates decreased from an SDI value of 0·3 upward (figure 4). Most regions saw a steady decrease over time, with values close to the expected line. Rates in Oceania and western subSaharan Africa remained mostly unchanged over the estimation period. Rates in central Asia and southern subSaharan Africa rose to a peak halfway through the estimation period and then declined.
About twothirds of the gap in agestandardised DALY rates between low SDI quintile countries (249·2 per 100 000 population [95% UI 202·3-307·6]) and high SDI quintile countries (110·6 per 100 000 population [84·2-143·7]) were due to a difference in YLL rates (126·92 per 100 000 population [114·81-140·13] for low SDI countries and 34·05 per 100 000 population [32·48-36·28] for high SDI countries), and onethird was due to lesser severity of disease as measured in YLDs. Prevalence of idiopathic epilepsy was similar among the quintiles of SDI. In 2016, there was a strong gradient in the prevalence of idiopathic epilepsy by severity. Low SDI quintile countries had the highest agestandardised prevalence of severe epilepsy and the lowest age standardised prevalence of treated epilepsy without seizures, with the opposite being the case in high SDI countries (table 2) .
The only risk quantified in GBD for idiopathic epi lepsy was alcohol use, estimated to be respons ible for 18·9% (95% UI 14·6-23·1) of global DALYs from epi lepsy in men (7 524 103·60 [6 254 535·71-9 024 594·20]) and 8·2% (5·8-10·5) in women (5 968 147·15 [4 760 417·45-7 452 692·07]).
Discussion
Between 1990 and 2016, a significant reduction was observed in the mortality rate in people with idiopathic epilepsy and, to a lesser extent, a reduction was found in DALY rates, a comprehensive measure of the burden of the disease, when adjusted for age. This finding probably reflects improvements in access to treatment leading to a lower risk of death and lesser severity of the disease. Nevertheless, a substantial treat ment gap remains (due to insufficient financial resources, misconceptions, and stigma 22 ) that can explain the larger proportion of severe epilepsies and higher case fatality when comparing high SDI with middle and low SDI countries.
Our estimate of 45·9 million cases of idiopathic active and secondary epilepsy in 2016 is higher than the 32·7 million cases reported from a metaanalysis of 65 prevalence studies, 7 but it seems that the estimate of the number of cases of active epilepsy in rural populations in lowincome countries was reported as 17 million in the metaanalysis, whereas our interpret ation of the results is that it should have been 37 million. Furthermore, it is not clearly stated for which year the estimate was made in the metaanalysis. However, similar to findings from that metaanalysis, large variations were observed in the prevalence of epilepsy in this study, but there was no clear pattern by development status or by location. This finding raises the question of how much of the variation we estimated between countries is real or an artifact of measurement error we have been unable to control for. The unknown cause of epilepsy, apart from an association with alcohol use, makes it difficult to fit estimates to sparse and heterogeneous data.
In 2016, epilepsy accounted for more than 13 million DALYs, that is 0·56% of total DALYs globally. The numbers are significantly higher than the projected estimates from WHO (7·4 million), 5 but the proportion of total DALYs attributable to epilepsy in the WHO report (0·50%) was almost identical despite multiple measure ment differ ences making results incomparable. In that report, epilepsy was defined in accordance with the 2005 ILAE and International Bureau for Epilepsy definition as 23 This definition is in keeping with the definition used in the present study. Other populationbased studies addressed the burden of epilepsy using the DALY metrics. These studies were done in China, 24 India, 25 and South Africa. 26 However, the results of these studies cannot be compared with ours because of the different methodology and the regional perspective. Apart from the major changes in how DALYs are defined since GBD 2010 (no more discounting or age weighting, a prevalence instead of incidence approach to measuring nonfatal outcomes, and disability weights derived from large population surveys rather than a small panel of health experts), the largest difference is that in the past decade, we have developed statistical models that can evaluate all available epidemiological evidence rather than relying on an analyst to determine a single data source to describe prevalence or incidence in a country.
Variables such as race or ethnicity and socioeconomic level might be also interrelated. Our and others' findings 6 support the concept that epilepsy and poverty might have a bidirectional association. The inverse association between the burden of epilepsy and sociodemographic status is in line with other neurological disorders 8 and with published reports from lowincome countries and from people with low incomes in highincome countries. [27] [28] [29] Inequalities in health might also vary among members of the same population. 30 Low socio economic status is also associated with risk factors for epilepsy. 31 We should, however, argue that if we find an important link between the development status of countries and epilepsy outcomes, it is likely that much larger variation in outcomes exists at the individual level depending on a person's socioeconomic attributes.
The major strength of this study is the worldwide assessment of the burden of all major diseases, including epilepsy, using the same methodology and modelling measures. Another strength is the continuous refinement of the available data through input from new original sources and the use of more sophisticated statistical methods as these develop. There are, however, some general and diseasespecific limitations. First, as original epidemiological data were not available for all countries, Bayesian statistical models were used to estimate deaths and disease prevalence for countries with missing information. The inclusion of data sources from new original studies in countries for which no data were available in a previous iteration of GBD can lead to more precise estimates that might vary considerably from previous predicted values. The annual updates of GBD provide an opportunity to improve on estimates as new data or new methods become available. Second, the disability weights used for the calculation of YLDs might not be uniform across populations and sociodemographic levels. However, population surveys in nine countries did not find systematic variation in disability weights across populations or within the same population as a function of education. 17, 32, 33 Third, the 95% UI used to define the precision of the estimates are wide, reflecting the overall uncertainty of the estimates and, as a consequence, limiting the ability to find differences across countries. This finding can explain why few countries showed a significant change in DALY rates. The main source of uncertainty around the incidence and prevalence estimates of idiopathic epilepsy comes from the sparse and heterogeneous data about the proportion of people with idiopathic as opposed to secondary epilepsy and, for idiopathic epilepsy, on the distribution of (presumed) genetic and cryptogenic forms. Likewise, deaths as part of idiopathic epilepsy might include deaths of people with secondary epilepsy. Further uncertainty comes from our definition of severity and the estimates of the proportion of people with severe epilepsy, people with less severe epilepsy, and those with no seizures while on treatment. A third source of uncertainty for the YLD estimates comes from the wide uncertainty bounds around the disability weights. New data collection on these various proportions that determine the sequelae of epilepsy would have the greatest bearing on reducing UIs. Fourth, epilepsy is correlated with somatic and psychiatric comorbidities 34 and injuries, 35 as well as a host of diseases associated with stigma and poverty. 36 Here, the correction for comorbidity was based on the assumption that diseases and their sequelae are independent. Future improve ments of the GBD modelling should include dependent comorbidity. Fifth, the use of medical claims data could introduce a systematic bias as people who are not under treatment or are excluded from health insurance would not be counted. For the 3 years of claims data from the USA, we applied a correction based on a comparison with representative survey data. In coming years, we hope to include claims data from other countries and more comprehensive claims data from the USA that are less biased towards individuals with private health insurance only. The challenge will be to find represen tative survey data in those countries to make credible adjustments. Sixth, the peak in DALY rates in southern subSaharan Africa coincides with the peak in deaths as a result of HIV or AIDS in 2005 and suggests that despite an effort to correct deaths miscoded to nonHIV causes in the South African vital registration data, we might have left some remaning deaths that should have been reassigned to HIV or AIDS. However, even if the peak is an artifact, these regions still have much higher than expected DALY rates for idiopathic epilepsy. The reason for the recorded increase and then decrease in deaths in vital registration data from central Asia is less clear. Seventh, the higher mortality rate of idiopathic epilepsy in some western European countries than in lowincome and middleincome countries cannot be easily explained and might reflect differences in cause of death certification practices. Last, epilepsy in this report is defined by having at least two unprovoked seizures and is in contrast with the recent ILAE definition that includes a single unprovoked seizure judged at high risk of relapse. 37 However, almost all published reports included patients with recurrent seizures and perhaps the inclusion of individuals with single seizures would increase the burden of the disease.
In conclusion, our findings have important impli cations for health service planning. The decrease in death and DALY rates in patients with epilepsy between 1990 and 2016 is encouraging, but the changes varied across geographical areas and, where data were available, within countries. Furthermore, changes were linked to the sociodemographic development status, which should prompt more action in economically deprived areas. The success of reducing the burden of idiopathic epilepsy relies mostly on access to treatment. Health service planners and providers also need to be aware that patients with epilepsy are more often poor and marginalised because of stigma, requiring a greater effort to reach them than might be the case for most other diseases.
